Literature DB >> 24515462

Screening and subcloning of high producer transfectomas using semisolid media and automated colony picker.

Suba Dharshanan1, Cheah Swee Hung.   

Abstract

Generation of high-producing clones is a perquisite for achieving recombinant protein yields suitable for biopharmaceutical production. However, in many industrially important cell lines used to produce recombinant proteins such as Chinese hamster ovary, mouse myeloma line (NS0), and hybridomas, only a minority of clones show significantly above-average productivity. Thus, in order to have a reasonable probability of finding rare high-producing clones, a large number of clones need to be screened. Limiting dilution cloning is the most commonly used method, owing to its relative simplicity and low cost. However the use of liquid media in this method makes the selection of monoclonal hybridoma and transfectoma colonies to be labor intensive and time consuming, thus significantly limiting the number of clones that can be feasibly screened. Hence, we describe the use of semisolid media to immobilize clones and a high-throughput, automated colony picker (ClonePix FL) to efficiently isolate monoclonal high-producing clones secreting monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24515462     DOI: 10.1007/978-1-62703-992-5_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential.

Authors:  Mateus Dalcin Luchese; Mariana Lopes Dos Santos; Angelica Garbuio; Roselaine Campos Targino; Carla Ploeger Mansueli; Lilian Rumi Tsuruta; Wagner Quintilio; Ana Maria Moro
Journal:  Immunol Res       Date:  2018-06       Impact factor: 2.829

2.  A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line.

Authors:  Martin Listek; Anja Hönow; Manfred Gossen; Katja Hanack
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.